Antischistosomal agents: state of art and perspectives

作者：Lago Eloi M; Xavier Rogerio P; Teixeira Thaina R; Silva Livia M; da Silva Filho Ademar A; de Moraes Josue^*

来源：Future Medicinal Chemistry, 2018, 10(1): 89-120.

DOI：10.4155/fmc-2017-0112

• chemogenomics
• drug discovery
• drug repositioning
• druggability
• high-throughput screening
• Hit
• lead
• molecular modeling

Praziquantel has remained the drug of choice for schistosomiasis chemotherapy for almost 40 years. The pressing need to develop a new antischistosomal drug may necessitate exploring and filtering chemotherapeutic history to search for the most promising ones. In this context, this review attempts to summarize all progress made in schistosomiasis chemotherapy from the early 20th century (mid-1910s) to 2016. We gathered almost 100 compounds providing information on therapeutic action, specifically covering at least first in vivo studies in animal model and in vitro. Pharmacokinetic and toxicity profiles of antischistosomal agents were also described. Preclinical studies indicate a handful of promising future candidates.

• 出版日期2018-1